Drugs Made In America Acquisition (NASDAQ:DMAA) Posts Earnings Results

Drugs Made In America Acquisition (NASDAQ:DMAA – Get Free Report) issued its quarterly earnings data on Monday. The company reported $0.05 earnings per share for the quarter, FiscalAI reports.

Drugs Made In America Acquisition Price Performance

Shares of NASDAQ:DMAA opened at $10.90 on Wednesday. Drugs Made In America Acquisition has a 52-week low of $10.32 and a 52-week high of $10.91. The stock has a 50 day moving average price of $10.87 and a 200-day moving average price of $10.66.

Institutional Investors Weigh In On Drugs Made In America Acquisition

Hedge funds have recently made changes to their positions in the company. Glazer Capital LLC purchased a new stake in Drugs Made In America Acquisition in the third quarter worth $9,279,000. First Trust Capital Management L.P. purchased a new position in Drugs Made In America Acquisition during the third quarter valued at $8,557,000. Finally, Sona Asset Management US LLC purchased a new position in Drugs Made In America Acquisition during the first quarter valued at $1,706,000.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has a consensus rating of “Sell”.

Read Our Latest Analysis on Drugs Made In America Acquisition

About Drugs Made In America Acquisition

(Get Free Report)

Drugs Made In America Acquisition Corp. is a special purpose acquisition company formed to pursue a merger, asset acquisition, or similar business combination. It does not operate a pharmaceutical business or manufacture drugs itself. The company’s stated focus was on identifying a business in the pharmaceutical industry, particularly one connected with drug manufacturing in the United States. Its activities were centered on seeking a suitable acquisition or merger candidate.

Further Reading

Receive News & Ratings for Drugs Made In America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.